Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Non-Hodgkin × Dexamethasone × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 105 Precursor Cell Lymphoblastic Leukemia-Lymphoma 15 Recurrence 12 Burkitt Lymphoma 10 Neoplasms 8 Immunoglobulin Light-chain Amyloidosis 8 Neoplasms, Plasma Cell 7 Prostatic Neoplasms 6 Neoplasm Metastasis 5 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4 Neoplasm, Residual 4 Lung Neoplasms 4 Leukemia, Biphenotypic, Acute 4 Carcinoma, Non-Small-Cell Lung 4 Paraproteinemias 3 Lymphoma, B-Cell 3 Lymphoma 3 Leukemia 3 Breast Neoplasms 3 Brain Neoplasms 3 Triple Negative Breast Neoplasms 2 Renal Insufficiency 2 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Ovarian Neoplasms 2 Lymphoma, Mantle-Cell 2 Lymphoma, Large B-Cell, Diffuse 2 Hodgkin Disease 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2

Interventions

Cyclophosphamide 21 Rituximab 18 fludarabine 15 obinutuzumab 9 fludarabine phosphate 9 pirtobrutinib 8 venetoclax 6 tocilizumab 6 ibrutinib 6 Specimen Handling 6 Lenalidomide 6 Immunotherapy, Adoptive 6 Biopsy 6 polatuzumab vedotin 5 glofitamab 5 Prednisone 5 Mycophenolic Acid 5 Magnetic Resonance Spectroscopy 5 X-Rays 4 Tacrolimus 4 Phantoms, Imaging 4 Doxorubicin 4 pembrolizumab 3 palbociclib 3 olaparib 3 axicabtagene ciloleucel 3 Whole-Body Irradiation 3 Vincristine 3 Vemurafenib 3 Thiotepa 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06230224 2026-02-06

OLYMPIA-4

Regeneron Pharmaceuticals

Phase 3 Recruiting

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡